Director, ALS Center of Oregon, Oregon Health & Science University
Associate Director, Neuromuscular Diseases Center of Oregon
Director, EMG LaboratoryAssociate professor of Neurology, OHSU
Dr. Lou earned his M.D. at the National University of Taiwan in 1979. He obtained a Ph.D. in Neurophysiology from the University of Minnesota in 1986. Dr Lou has held positions at the National Institute of Neurological Disorders and Stroke at the NIH, the University of Rochester, and the Barrow Neurological Institute. Before joining OHSU Dr Lou served as Research Director for the Muhammad Ali Parkinson Research Center.
Dr Lou's research interests lie in the areas of ALS and Parkinson's disease. He is currently involved in a study on the use of antibiotics in ALS patients, a study of the benefits of creatine in ALS, as well as two project dealing with treatment of Myasthenia Gravis.
Carter GT, Weiss MD, Lou JS, Jensen MP, Abresch RT, Martin TK, Hecht TW, Han JJ, Weydt P,Kraft GH. Modafinil in amyotrophic lateral sclerosis: an open label pilot study. Am J Hosp Palliat Med 2005 22(1):55-59.
Lou JS, Benice T, Sexton G, Nutt J. Levodopa normalizes exercise related cortico-motoneuron excitability abnormalities in Parkinson’s disease. Clinical Neurophysiology 2003;114:930-937.
Fried-Oken M, Fox L, Rau MT, Tullman J, Lou JS. Using augmentative communication technology to interact: Why caregivers and persons with ALS converse. Presented at the 14th International symposium on ALS/MND, November, 2003, Milan. ALS and other motor neuron disorders 2003;4 (Supp1): 219.